Duojia Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Duojia Cao has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Alison Banham
Dept. of Clinical Laboratory Sciences, John Radcliffe Hospital, Oxford, United Kingdom
1 shared publicationAnn-Kristin Ulfgren
Unit of Rheumatology, Karolinska Institutet, Stockholm, Sweden
1 shared publication- Christina Trollmo
Rheumatology Unit, Department of Medicine at Karolinska University Hospital Solna, Karolinska Institutet, Stockholm; and
1 shared publication - Giovanna Roncador
Monoclonal Antibodies Unit, Spanish National Cancer Research Center (CNIO), Centro Nacional de Investigaciones Oncologicas, C/Melchor Fernandez Almagro, 3, 28029 Madrid, Spain
1 shared publication - Lars Klareskog
Department of Medicine, Division of Rheumatology, Karolinska Institutet, and Center for Molecular Medicine (CMM), Karolinska University Hospital, Stockholm, Sweden
1 shared publication Mona Widhe
Unit of Rheumatology, Karolinska Institutet, Stockholm, Sweden
1 shared publication
Latest Publications
- 31 December 2006
- Published by Elsevier in Clinical Immunology
- Vol. 119, S21
OR.46. Comparative Analysis of Foxp3 in Target Organ and Circulation of Rheumatic Patients
- 31 December 2006
- Published by Elsevier in Clinical Immunology
- Vol. 119, S21
OR.46. Comparative Analysis of Foxp3 in Target Organ and Circulation of Rheumatic Patients
- Open Access
- 7 June 2004
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 6 (4) , R335-46
CD25brightCD4+regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease
CD25+CD4+ regulatory T cells participate in the regulation of immune responses. We recently demonstrated the presence of CD25brightCD4+ regulatory T cells with a capacity to control T cell proliferation in the joints of patients with rheumatoid arthritis. Here, we investigate a possible accumulation of these regulatory T cells in the inflamed joint of different rheumatic diseases including rheumatoid arthritis. The studies are also extended to analyze whether cytokine production can be suppressed by the regulatory T cells. Synovial fluid and peripheral blood samples were obtained during relapse from 36 patients with spondyloarthropathies, 21 adults with juvenile idiopathic arthritis and 135 patients with rheumatoid arthritis, and the frequency of CD25brightCD4+ T cells was determined. Of 192 patients, 182 demonstrated a higher frequency of CD25brightCD4+ T cells in synovial fluid than in peripheral blood. In comparison with healthy subjects, the patients had significantly fewer CD25brightCD4+ T cells in peripheral blood. For functional studies, synovial fluid cells from eight patients were sorted by flow cytometry, and the suppressive capacity of the CD25brightCD4+ T cells was determined in in vitro cocultures. The CD25brightCD4+ T cells suppressed the production of both type 1 and 2 cytokines including interleukin-17, as well as proliferation, independently of diagnosis. Thus, irrespective of the inflammatory joint disease investigated, CD25brightCD4+ T cells were reduced in peripheral blood and enriched in the joint, suggesting an active recruitment of regulatory T cells to the affected joint. Their capacity to suppress both proliferation and cytokine secretion might contribute to a dampening of local inflammatory processes.
- 7 June 2004
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 6 (4) , R335-46
Open AccessCD25brightCD4+regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease
CD25+CD4+ regulatory T cells participate in the regulation of immune responses. We recently demonstrated the presence of CD25brightCD4+ regulatory T cells with a capacity to control T cell proliferation in the joints of patients with rheumatoid arthritis. Here, we investigate a possible accumulation of these regulatory T cells in the inflamed joint of different rheumatic diseases including rheumatoid arthritis. The studies are also extended to analyze whether cytokine production can be suppressed by the regulatory T cells. Synovial fluid and peripheral blood samples were obtained during relapse from 36 patients with spondyloarthropathies, 21 adults with juvenile idiopathic arthritis and 135 patients with rheumatoid arthritis, and the frequency of CD25brightCD4+ T cells was determined. Of 192 patients, 182 demonstrated a higher frequency of CD25brightCD4+ T cells in synovial fluid than in peripheral blood. In comparison with healthy subjects, the patients had significantly fewer CD25brightCD4+ T cells in peripheral blood. For functional studies, synovial fluid cells from eight patients were sorted by flow cytometry, and the suppressive capacity of the CD25brightCD4+ T cells was determined in in vitro cocultures. The CD25brightCD4+ T cells suppressed the production of both type 1 and 2 cytokines including interleukin-17, as well as proliferation, independently of diagnosis. Thus, irrespective of the inflammatory joint disease investigated, CD25brightCD4+ T cells were reduced in peripheral blood and enriched in the joint, suggesting an active recruitment of regulatory T cells to the affected joint. Their capacity to suppress both proliferation and cytokine secretion might contribute to a dampening of local inflammatory processes.